Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell line issues: historical and future perspectives.

J C Petricciani1

  • 1Pharmaceutical Manufacturers Association, Washington, DC 20005.

Developments in Biological Standardization
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The acceptability of continuous cell lines: A personal & historical perspective.

Cytotechnology·2012
Same author

An overview of viral and viral-like agents in cell culture systems.

Cytotechnology·2008
Same author

Recent trends in cell substrate considerations for continuous cell lines.

Current opinion in biotechnology·2001
Same author

Recombinant DNA vaccines and therapeutics.

Lancet (London, England)·2000
Same author

International acceptance of blood and blood products.

Developments in biologicals·2000
Same author

Cell substrates: lessons learned and challenges remaining.

Developments in biological standardization·2000
Same journal

International challenges and public policy issues.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in China.

Developments in biological standardization·2000
Same journal

ICH activities on biotech topics.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in the European Union.

Developments in biological standardization·2000
Same journal

Standardisation and licensing of combination vaccines based on DTP.

Developments in biological standardization·2000
Same journal

Control of foot-and-mouth disease by vaccination.

Developments in biological standardization·2000
See all related articles

Human diploid cells (HDCs) and continuous cell lines (CCLs) have been debated for biological product manufacturing. Modern processes can manage contaminants, supporting CCL use for product development.

Area of Science:

  • Biotechnology
  • Cell Biology
  • Regulatory Science

Background:

  • Historically, primary cell cultures were standard for human biological products.
  • Human diploid cells (HDCs) and later continuous cell lines (CCLs) challenged this standard, sparking regulatory debate.
  • Recombinant DNA technology increased the urgency for CCL acceptance in product development.

Observation:

  • The history of the HDC controversy offers relevant lessons for CCL adoption.
  • A 1986 World Health Organization Study Group reviewed CCL safety for product derivation.
  • Modern manufacturing demonstrates capability in managing contaminants associated with CCLs.

Findings:

  • The WHO Study Group recommended pursuing CCLs in product development.
  • Key issues for discussion include acceptable cellular DNA levels and product purity.

Related Experiment Videos

  • The genetic stability of recombinant cells is crucial for product consistency.

    • Implications:

    • Cooperation between regulatory authorities, industry, and the scientific community is essential.
    • Addressing cellular DNA, purity, and genetic stability will facilitate CCL use.
    • Continued dialogue is needed to establish consensus on regulatory issues for biological product manufacturing.